	US 12,109,305 B2
	Materials architecture for gastric residence systems
Andrew Bellinger, Wellesley, MA (US); Rosemary Kanasty, Somerville, MA (US); Tyler Grant, Arlington, MA (US); Nupura Bhise, Cambridge, MA (US); Robert Debenedictis, Cambridge, MA (US); Jung Yang, Brookline, MA (US); Stephen Zale, Hopkinton, MA (US); and John Klier, Cambridge, MA (US)
Assigned to LYNDRA THERAPEUTICS, INC., Watertown, MA (US)
Appl. No. 16/303,118
Filed by Lyndra Therapeutics, Inc., Watertown, MA (US)
PCT Filed May 26, 2017, PCT No. PCT/US2017/034856 § 371(c)(1), (2) Date Nov. 19, 2018, PCT Pub. No. WO2017/205844, PCT Pub. Date Nov. 30, 2017.
Claims priority of provisional application 62/342,798, filed on May 27, 2016.
Prior Publication US 2019/0254966 A1, Aug. 22, 2019
Int. Cl. A61K 9/00 (2006.01); A61F 5/00 (2006.01); A61K 47/34 (2017.01); A61L 31/04 (2006.01); A61L 31/06 (2006.01); A61L 31/16 (2006.01)

CPC A61K 9/0065 (2013.01) [A61F 5/0036 (2013.01); A61K 47/34 (2013.01); A61L 31/06 (2013.01); A61L 31/16 (2013.01); A61L 31/048 (2013.01); A61L 2300/602 (2013.01); A61L 2300/604 (2013.01)]

34 Claims

1. A co-extruded elongate member comprising;

at least one carrier polymer-therapeutic agent (or salt thereof);

at least one disintegrating linker, wherein the at least one disintegrating linker is a time-dependent linker and is configured to weaken to cause the elongate member to decouple or weaken; and

a reinforcing material comprising one or more of polycaprolactone (PCL), polydioxanone, polylactic acid, polycarbonate, polyether ether ketone, polyethylene, or polypropylene,

wherein the disintegrating linker comprises PCL, and

wherein the reinforcing material extends axially along the co-extruded elongate member,

wherein said elongate member is configured for use in a stellate gastric residence system having a gastric residence time between about 48 hours and one month.